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A B S T R A C T   
Background: Melanotic schwannoma is a rare variant of schwannoma. Extramedullary melanotic schwannoma 
originates in the vicinity of nerve roots mimicking other intervertebral disc disorders. Therefore, T1 and T2- 
weighted MRI sequences become an essential tool for diagnosis. Aside from case reports, no large studies exist 
to provide consensus on the signal intensities in T1 and T2-weighted MR imaging. Moreover, no clear evidence is 
available to delineate prognosis. Here, a case report is presented together with a subsequent systematic review of 
the literature regarding this rare entity. 
Case description: A 45-year old female presented with a one-year history of insidious onset of neck pain and 
paraesthesia. Magnetic resonance imaging confirmed an extramedullary lesion along the C6 nerve root with T1- 
weighted hyperintensity and T2-weighted hypointensity. Despite two surgical decompressions and adjuvant 
immunotherapy, the patient unfortunately passed away due to metastatic progression. 
Discussion: According to the systematic review conducted, in over half of the cases of extramedullary melanotic 
schwannoma, there is local reoccurrence and/or distal metastasis. Moreover, in 64.7% and 70.6% of the cases, 
the T1-weighted image of the lesion appears hyperintense and hypointense on a T2-weighted image, respec-
tively. It is an aggressive variant of schwannoma, one of the most commonly observed extramedullary tumours 
presenting to neurosurgical practice. 
Conclusion: Our results highlight that specific T1 and T2-weighted imaging findings can provide valuable in-
formation, enabling early suspicion, influencing the surgical aims and strategy and the timely commencement of 
relevant immunotherapy. Considering the poor prognosis, early adjuvant therapy with other modalities should 
be considered.   
1. Introduction 
Schwannomas are solitary, encapsulated and slow-growing neo-
plasms composed of Schwann cells constituting the nerve sheath [1]. 
Melanotic schwannoma (MeS) or melanocytic schwannoma, initially 
described by Millar in 1932 [2], is a rare variant composed of neoplastic 
Schwann cells that produce melanin and account for less than 1% of 
primary peripheral nerve sheath tumours [1]. It is hypothesized that 
Schwann cells are capable of synthesizing melanin, owing to a common 
progenitor of both Schwann cells and melanocytes being migrating 
neural crest cells [3]. Macroscopically, they appear black, brown or dark 
blue in colour, whereas under light microscopy, there is evidence of 
heavy melanin deposition, spindle morphology, nuclear pleomorphism 
and low mitotic rate with or without psammoma bodies [4,5]. To date, 
approximately 200 cases of MeS have been described in the literature, 
predominantly as case reports, but also some small case series. Posterior 
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nerve roots represent the most frequently involved site (30.5%) [6], but 
MeS affecting the spinal cord, sympathetic chain, cranial nerve roots, 
peripheral nerves and the gastrointestinal tract [7–12] have also been 
documented. It is generally accepted that MeS can be divided into 
psammomatous and non-psammomatous [13–15] subtypes. In 1990, 
Carney described the psammomatous MeS as a distinct clinicopathologic 
entity and proposed it be considered as part of the Carney complex in 
conjunction with the presence of cutaneous lesions, endocrine tumours 
and cardiac myxoma [13]. A Mendelian dominant hereditary pattern 
was then defined as being responsible for the clinical phenotype [16]. 
Extramedullary MeS presents in similar fashion to other extramedullary 
spinal tumours. Originating in the vicinity of the spinal nerve roots, it 
often leads to compression within and narrowing of the intervertebral 
foramen, leading to the manifestations of radicular pain, back pain, 
dysesthesias and progressive sensory and motor deficits. The 
non-specific combination of radicular pain and back pain can often lead 
to the clinical misdiagnosis of an intervertebral disc disorder. As the 
tumour grows, it leads to the progression of motor and sensory signs 
with Magnetic Resonance Imaging (MRI) guided assessment, an 
important diagnostic tool [17]. 
Until 1998, the MRI characteristics of MeS of the spine had not been 
described. Bendszus et al. originally described the lesion to appear 
hyperintense in T1 and hypointense in T2 [18]. There have been no 
extensive reviews focusing on the imaging of MeS, although it has been 
globally accepted that it has a characteristic hyperintensity on 
T1-weighted sequence and hypointensity on T2-weighted sequence 
[19]. Clinically, several studies have commented on the malignant and 
metastatic potential of MeS, however, with heterogeneous outcomes 
[12,51,57]. We describe and discuss a case of rare fulminant MeS with 
distal and local metastases, and provide a systematic review of both 
imaging as well as prognostic outcomes regarding MeS, including 
highlighting its metastatic potential. 
2. Case report 
2.1. History 
A 45-year-old female patient of white ethnic background was 
referred to the neurosurgical service by the spinal physiotherapy 
department. She presented with a one-year history of insidious neck pain 
radiating to the shoulder girdle, left arm and thumb, with associated 
paraesthesia in the same distribution. The pain was worse on resting and 
relieved by non-steroidal anti-inflammatory drugs (NSAIDs). An initial 
diagnosis of C6 radiculopathy was made and, given the failure of con-
servative management, she was offered a contrast-enhanced MRI. The 
only relevant past medical history was that of hiatus hernia and thyroid 
adenoma for which she had a partial thyroidectomy 10 years previously, 
with levothyroxine as the only regular medication. No family history of 
malignancy was found. 
2.2. Radiological findings 
Cervical spine imaging revealed a dumbbell-shaped lesion along the 
C6 nerve root, with both intradural and extradural components. The 
central portion of the extradural component, in particular, demonstrated 
T2 hypointensity on most sequences, while the peripheral portions 
enhanced homogeneously (‘target’ sign, consistent with a peripheral 
nerve sheath tumour [usually suggestive of neurofibroma, but also seen 
in schwannomas and malignant peripheral nerve sheath tumours]) [20]. 
The overall appearances were consistent with schwannoma (Fig. 1). 
2.3. Surgical approach/management 
Following discussion at the neuro-oncological multi-disciplinary 
team (MDT) meeting, a recommendation for surgical excision was made. 
A C5/6 left hemilaminectomy was performed under intra-operative 
neurophysiological monitoring (IONM). Post-operatively, the patient 
showed improvement of symptoms in the left arm. 
2.4. Histopathological findings 
Histology revealed a heavily pigmented spindle cell neoplasm, ar-
ranged in solid sheets and fascicles, with focal epitheloid differentiation 
and several well-defined areas of necrosis. The individual tumour cells 
displayed nuclear pleomorphism with prominent nucleolation and well- 
defined basophilic cytoplasm with finely granular brown pigment 
consistent with neuromelanin. Mitoses amounted to 3/single high power 
field (×40 objective). Psammoma bodies were absent. Immunohisto-
chemistry showed a nuclear labelling index for the proliferation marker 
ki-67 of up to 25%, and strong staining for S100, MelanA and HMB45, 
while pancytokeratin CK AE1/3 was negative. Histochemistry for 
reticulin demonstrated predominantly pericellular collagen staining in 
the tumour, while focal loss of pericellular reticulin deposition was 
noted in some areas. A diagnosis of ‘malignant melanotic spindle cell 
neoplasm, consistent with malignant melanotic schwannoma’, based on 
the anaplastic histological features in this biopsy, was confirmed. 
The latest edition of the WHO classification of tumours of the central 
nervous systems (2016) has not yet assigned a grade for this variant, but 
its aggressive behaviour reported in the literature suggests a grade of at 
least WHO III. Genetic analysis was negative for BRAF V600 mutation, 
Fig. 1. A) Pre-operative magnetic resonance imaging (MRI) in T2 (superior plates) and T1 (inferior plates) weighted imaging sequences. Axial (left) and Sagittal 
(right) sequences presented. The left-sided dumbbell shaped lesion is visualised extending through the intervertebral foramen with both intra-dural intra-canalicular 
and extra-dural extra-canalicular elements. The T1 weighted sequence demonstrates the characteristic ‘target’ sign with central hypo-intensity with circumferential 
peripheral enhancement. b) Post-operative MRI in similar configuration demonstrating near total excision of the lesion. A small focus of contrast-enhancement intra- 
dural and intra-canalicular is visualised representing possible residual remnant. 
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and PD-L1 expression was absent. Further genetic studies were not un-
dertaken. Although the histology was most in keeping with a malignant 
melanotic schwannoma, at MDT, a dermatological review was recom-
mended to rule out the possibility of metastatic malignant melanoma. 
2.5. Further management 
In light of histology and MDT discussion, the patient was referred to 
dermatology for an urgent review and staging computerised tomogra-
phy (CT) scan of the chest, abdomen and pelvis. 
CT at the time showed no evidence of peripheral metastases, whilst 
dermatology review revealed a 6mm asymmetrical ugly duckling naevus 
in the skin over the left knee [21]. There was no clinical evidence of 
Carney’s complex. The skin lesion was then biopsied, which was diag-
nosed as a pT1a AJCC stage group 1a melanoma (Fig. 2). Wide local 
excision of the skin lesion was advised to ensure clear margins. 
Re-exploration to achieve gross total resection of the extradural 
portion of the spinal tumour, as well as amputation of the C6 nerve root 
for local control was recommended. Pre-operatively, left vertebral artery 
occlusion was performed to reduce tumour vascularity and optimise the 
feasibility of achieving gross total resection. An anterior cervical 
approach was attempted but owing to significant tumour adherence, a 
subsequent revision posterior approach was required to accomplish 
gross total resection of the lesion and amputation of the nerve root. 
2.6. Post-operative outcomes 
After surgery, the patient experienced transient dysphagia due to 
post-surgical cervical haematoma, which responded well to conservative 
management with dexamethasone. Post-operative imaging confirmed 
excision of the majority of the residual enhancing lesion, with only a 
small residuum remaining. Adjuvant radiotherapy was commenced two 
months after surgery. 
Three months following the completion of radiotherapy, the patient 
developed right-sided hip pain and subsequent imaging revealed a large 
metastasis in the right femoral neck that resulted in a pathological 
intracapsular fracture of the right femoral neck. A right hip hemi-
arthroplasty was thus carried out. In light of the bone metastasis, 
another staging CT was performed, revealing multiple lung metastases 
and possible liver metastasis. The patient was subsequently started on 
combination immunotherapy involving Nivolumab, an antibody against 
programmed death 1 (PD-1) receptor, Ipilimumab, an antibody against 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) as well as 
Denosumab, Receptor activator of nuclear factor kappa-В (RANK) 
ligand-specific antibody [22,23]. 
Unfortunately, the patient’s disease progressed despite treatment. 
She was readmitted to the hospital one month following the start of 
immunotherapy for bilateral pleural effusions, as well as pneumonia. 
Due to a rapid decline in her functional and performance status, palli-
ative care and support was initiated. The patient passed away shortly 
after, within 15 months of diagnosis. The case report was written in 
retrospect and as such the patient’s perspective was not feasible to be 
included. 
2.7. Review of the literature and discussion 
A systematic literature review was conducted across known data-
bases, PubMed, EMBASE, Medline and reviewed the reported cases of 
extramedullary spinal MeS to date. A total of 65 cases were identified 
with the diagnosis of MeS (Table 1) across 46 published papers. 
In 61/65 (93.8%) cases, the gender was available, of which 33/61 
(54.1%) were male, and 28/61 (45.9%) were female — patients with 
extramedullary MeS most commonly presented between 30 and 40 years 
of age (Fig. 3). 
In 37/65 of the cases, information regarding metastasis was avail-
able. In 19/37 (51.4%) cases, evidence of metastasis or local recurrence 
was found, of which 9/37 (24.3%) had both distal metastasis and local 
recurrence, 5/37 (13.5%) had local recurrence in isolation, and 5/37 
(13.5%) had distal metastasis in isolation (Fig. 4). In 18/37 (48.6%), no 
evidence of recurrence or metastases were noted. Notably, the follow-up 
time across studies was highly variable, ranging from a few months up to 
two years. 
Fig. 2. A) HE ×100 mag.: Heavily pig-
mented spindle cell neoplasm with epithe-
lioid component (bottom) and necrosis 
(top). Psammoma bodies are absent. b) Ki67 
× 40 mag.: Nuclear labelling index amounts 
to ~25% throughout [3 mitoses in one high 
power field (×40 objective), not illustrated]. 
c) MelanA x 200 mag.: Small clusters of 
immunopositive cells (on the right). In 
contrast, heavy intrinsic pigmentation on the 
left. Tumour cells contain oval, prominently 
nucleolated nuclei and well-defined baso-
philic cytoplasm with finely granular 
pigment consistent with neuromelanin. d) 
Reticulin x 100 mag. [b]: Prominent peri-
cellular reticulin deposition overall but focal 
clusters of tumour cells (centre) lack peri-
cellular wrapping. Inset: Prominent peri-
cellular deposition in spindle cell areas.   
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Table 1 
Shows the number of MeS cases found in the literature. Level of lesion, age, gender, metastatic potential and T1-weighted and T2-weighted MRI imaging findings.  
Level Gender Age Reference Metastasis Region MRI T1 MRI T2 
Cervical        
C1 M 34 [6] yes Local and distal – – 
C1 – – [19] – – – – 
C1 M 54 [24] no N/A hyperintense hypointense 
C2 F 30 [17] yes local hyperintense  
C2-3 F 66 [25]a –    
C2-3 F 35 [12] yes Local and distal – – 
C4 M 36 [26] yes distal   
C4 – – [19] – – – – 
C4-5 F 32 [27] yes distal hyperintense hypointense 
C5-6 F 53 [28] no N/A isointense hyperintense 
C6 F 26 [29] no N/A – – 
C6-7 M 27 [30] yes local – – 
C7 M 64 [10] yes Local and distal hyperintense hypointense 
C8 F 49 [31] –    
C8 F 49 [32] no N/A – – 
Thoracic        
T1-T1 F 17 [18] no N/A hyperintense hypointense 
T2 F 45 [33]a – – – – 
T2 F 12 [31]a – – – – 
T2-4 M 47 [34] no N/A hyperintense hypointense 
T3 F 40 [35] no N/A   
T5 M 38 [36] no N/A – – 
T6-7 M 40 [37]a – – – – 
T6 M 34 [6] yes distal – – 
T6-8 F 65 [38] yes local hyperintense – 
T7 M 59 [39] yes local   
T7 M 25 [40] yes Local and distal hyperintense hypointense 
T7 M 61 [41]a – – – – 
T8-12 M 67 [42] no N/A hyperintense hypointense 
T9 M 43 [12] – – – – 
T9-10 M 53 [8] no N/A hyperintense hypointense 
T10 F 58 [43]a –    
T12-L1 F 17 [44] no N/A – – 
T12-L2 – – [45]a – – – – 
Lumbar        
L1 F 23 [41]a – – – – 
L1 M 32 [12] no N/A – – 
L1-2 M 43 [46] no N/A hypointense hyperintense 
L1-2 M 22 [47] no N/A hypointense hyperintense 
L1-2 F 75 [19] – – – – 
L2 M 42 [19] – – – – 
L2 M 37 [48]a – – – – 
L1-5 F 35 [19] – – – – 
L3 F 70 [49]a –    
L3 F 46 [50] yes local hyperintense hyperintense 
L3-5 F 35 [6] yes Local and distal – – 
L4 M 59 [51] yes Local and distal – – 
L4 F 40 [12] yes Distal and local – – 
L4-5 M 60 [49] – – hyperintense hypointense 
L5 M 27 [6] yes distal – – 
L5-S1 M 28 [52] yes Local and distal hyperintense – 
L5-S1 M 36 [53] – – – – 
L5-S1 M 33 [38] yes Local and distal – – 
L5-S1 F 36 [50] yes local hyperintense mixed 
Sacral        
S1 F 26 [54] no N/A – – 
S1 M 36 [51]a – – – – 
S1 F 63 [18]a – – – – 
S1 F 41 [6] no N/A – – 
Level Unknown        
N/A M 46 [55] no N/A – – 
N/A – – [8] no N/A – – 
N/A F 56 [56] – – – – 
N/A M 58 [56] – – – – 
N/A M 32 [57]a – – – – 
N/A M 35 9[19] – – – – 
N/A M – [58] – – mixed hypointense 
N/A M – [58] – – mixed hypointense 
N/A F – [58] – – mixed hypointense  
a No access to full article or the article was not available in English. 
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Regarding the radiological findings (Fig. 5), in 17/65 cases, both T1 
and T2-weighted MRI sequences were available. The T1-weighted im-
aging was hyper-intense in the majority (11/17) with the rest demon-
strating either mixed (3/17), hypo-intense (2/17) or iso-intense (1/17) 
signal changes. The T2-weighted imaging was predominantly hypo- 
intense (12/17) with a minority showing either hyper-intense (4/17) 
or mixed (1/17) signal intensities. 
A number of case reports and a small number of case series share 
common thoughts regarding the histological classification, incidence 
and management of extramedullary MeS. According to the recent liter-
ature [34,50], there are two topics, which are still under discussion and 
subject to further evaluation regarding MeS. These are the T1-and 
T2-weighted MRI findings of MeS and the future prognosis regarding 
local recurrence and distant metastasis. According to our knowledge, 
there are no attempts to capture and summarise the radiological and 
prognostic evidence to date. Here, we endeavour to discuss our results in 
the context of the literature. 
The literature review conducted, revealed similar age distribution to 
other studies, with 30–40 years of age being the most common age of 
presentation [6,7]. Moreover, the gender distribution revealed a 1.2:1 
male to female ratio similar to other studies focusing on MeS [6,7,17]. 
It is widely accepted that MeS exhibit T1-weighted hyperintensity 
and T2-weighed hypointensity. On the contrary, schwannomas exhibit 
hypointensity on T1 and hyperintensity on T2. The review of 65 cases 
conducted, revealed that 64.7% of cases of MeS appear hyperintense, 
and 70.6% of cases appear hypointense in T1-and T2-weighted MRI 
sequences, respectively. Melanin exhibits paramagnetic effects, result-
ing in stable free radicals [59–61]. In essence, melanin protons have 
shorter T1 & T2 relaxation times. Therefore they quickly recover after an 
MRI pulse, and are able to appear brighter, leading to a hyperintense and 
hypointense T1 and T2 signals, respectively. The concentration of 
melanin and the density of the tumour are however not always 
consistent. 
Notably, Liu et al. showed that 95% of primary spinal melanomas 
showed T1 and T2-weighted hyper and hypointensity, respectively [62]. 
Since higher melanin concentration was associated with higher 
T1-weighted signal intensities and lower signal intensities on 
T2-weighed images [61], tumours which have melanocytes as their cell 
origin might have a greater concentration of melanin compared to MeS. 
Thus, having even slower relaxation times and being less affected by the 
surrounding environment leads to higher specificity of T1 and T2 hyper- 
and hypointense signals, respectively. 
Moreover, haemorrhage is common in CNS tumours [63]. 
Deoxy-haemoglobin and all iron-containing haeme groups exhibit 
paramagnetic effects. Timing of bleeding is also important: acute hae-
morrhage shows similar MRI findings to MeS (hyperintense T1 and 
hypointense T2), whereas subacute haematoma might show 
hyper-intense signal on T1 and hypo-intense T2-weighted images as well 
[64]. Therefore, melanin concentration and the extent and timing of 
haemorrhage are all of great significance to the MRI findings. 
The identification of a coincidental cutaneous melanoma in our pa-
tient raised the question whether the skin lesion and the spinal tumour 
were causally related and whether the latter represented a metastatic 
malignant melanoma. However, the skin lesion was in an early, micro- 
invasive stage with very low metastatic potential. In addition, both 
radiological and histological features of the spinal tumour strongly 
favoured melanotic schwannoma over melanoma, and paraspinal loca-
tion of metastatic melanoma is rare. 
With regards to prognosis, an early literature review by Vallat- 
Decouvelaere [6] identified a metastatic disease in up to 26% of pa-
tients with MeS. More recently, Zhan et al. demonstrated that MeS could 
metastasize in 9.1% of the cases and recurred locally in 18.2% of the 
cases after resection [12]. Interestingly, Torres-Mora et al., in one of the 
largest studies on MeS to date, have found that MeS tumours are 
significantly more aggressive than previously thought, with local 
recurrence in 35% of the cases and evidence of metastasis reaching 44% 
[5]. The group concludes that MeS is a distinctive malignant tumour, 
rather than benign neoplasm with occasionally unpredictable behav-
iour, proposing its reclassification as “malignant melanotic schwannian 
tumour". 
The comprehensive literature review conducted here, reveals that 
more than half of the cases (51.4%) are reported to have local or distal 
metastasis or both, confirming the suspicion that MeS is an aggressive 
neoplasm with high malignant potential. The aforementioned case 
Fig. 3. Percentage of patients versus age at diagnosis. Median age of presen-
tation is 20–40 years of age. 
Fig. 4. Percentage of patients versus metastasis and/or local reoccurrence. The 
majority of the cases show metastasis and/or local reoccurrence. 
Fig. 5. Percentage of patients with T1 & T2 MRI available versus signal in-
tensity per sequence. 
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report, written in accordance to the SCARE 2018 guidelines [ ], adds 
further value to the suspicion that MeS is an aggressive malignancy. 
3. Conclusion 
Melanotic schwannoma is a rare, aggressive and potentially malig-
nant variant of schwannoma, one of the most commonly observed 
intradural extramedullary tumours in neurosurgical practice. A high 
degree of suspicion is required in the context of imaging findings 
demonstrating T1 hyperintensity and T2 hypointensity on MRI. Early 
screening with whole-body staging CT should be considered owing to 
the risk of distant metastases. The surgical strategy should be aimed at 
considering a gross total resection for optimal local control. This may 
necessitate intra-operative histological analysis by way of a frozen sec-
tion to guide the extent of resection. Early follow-up and regular sur-
veillance imaging are advisable. Further studies are required concerning 
adjuvant therapy in the treatment and whether this should be consid-
ered in all cases or only following a recurrence or metastatic disease. 
Funding 
Not applicable. 
Availability of data and material 
Table 1 includes all articles we used to conduct the literature review. 
Consent for publication 
Written informed consent was obtained from the patient for publi-
cation of this case report and accompanying images. A copy of the 
written consent is available for review by the Editor-in-Chief of this 
journal on request. 
Provenance and peer review 
Not commissioned, externally peer reviewed. 
Funding 
No source of funding to declare. 
Ethical approval 
Research studies involving patients require ethical approval. Please 
state whether approval has been given, name the relevant ethics com-
mittee and the state the reference number for their judgement. Patients 
consent was obtain prior to writing the case report. 
Author contribution 
Please specify the contribution of each author to the paper, e.g. study 
concept or design, data collection, data analysis or interpretation, 
writing the paper, others, who have contributed in other ways should be 
listed as contributors. 
GS, TN, SA, have all contributed to the study design, data collection, 
data analysis, drafting and structuring the case report. 
WA and PU, have contributed in the data collection, analysis and 
writing the paper. 
Declaration of competing interest 
No conflict of interest to declare. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.amsu.2020.10.003. 
References 
[1] C. Santaguida, A.J. Sabbagh, M.C. Guiot, R.F. Del Maestro, Aggressive 
intramedullary melanotic schwannoma: case report, Neurosurgery 55 (6) (2004 
Dec 1) E1430–E1434. 
[2] W.G. Millar, A malignant melanotic tumour of ganglion cells arising from a 
thoracic sympathetic ganglion, J. Pathol. Bacteriol. 35 (3) (1932) 351–357. 
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